Background: Metabolic information provided by 18F-FDG PET/CT are useful for initial
staging, therapy planning, response evaluation, and to a lesser extent for the follow-up of …

PET and 18F-FDG have the potential to follow the early metabolic response to
chemotherapy in patients with non–small cell lung cancer and to predict success or failure of …

Molecular imaging with PET, and certainly integrated PET-CT, combining functional and
anatomical imaging, has many potential advantages over anatomical imaging alone in the …

Despite recognized limitations, structural imaging with CT remains the standard technique
for evaluating the response of lung cancer to both chemotherapy and radiotherapy. This …

The potential of 18F-FDG PET changes was evaluated for prediction of response to
concomitant chemoradiotherapy in patients with locally advanced non–small cell lung …

This study investigated the possibility of early response assessment based on 18F-FDG
uptake during radiotherapy with respect to overall survival in patients with non–small cell …

Materials and Methods: Thirty-one patients (23 males, 8 females with an age range of 42–77
years) with Epidermal Growth Factor Receptor (EGFR) positive metastatic lung cancer on …

Purpose To assess prospectively the prognostic value of FDG PET/CT during curative-intent
radiotherapy (RT) with or without concomitant chemotherapy in patients with non-small-cell …

Change in 18F-FDG uptake may predict response to anticancer treatment. The PERCIST
suggest a threshold of 30% change in SUV to define partial response and progressive …

PET/CT with the glucose analog 18F-FDG has several potential applications for monitoring
tumor response to therapy in patients with non–small cell lung cancer (NSCLC). A …